Gene Expression Technologies Ltd.

Gene Expression Technologies Ltd. (GET) aims to use its novel Gene Inactivation by Chromatin Engineering (GeneICE) platform to achieve complete and accurate gene silencing, while maintaining the flexibility and speed embodied by RNAi and antisense technologies currently used for silencing-based drug target validation. GET's GeneICE constructs are also being tested as potential therapeutics.

Gene silencing—down-regulating the expression of a specific gene-product, or protein—is an invaluable tool used by researchers to validate drug targets. Of the many ways scientists have attempted to silence genes, only one—the homologous mouse model, in which individual genes are knocked-out one by one from an animal's genetic code—unambiguously achieves complete and accurate silencing of genes, claims [Gene Expression Technologies Ltd.] (GET) CEO Cameron Macdonald, PhD.

But the mouse model is inflexible, requires months to develop, and cannot be extrapolated for use in humans. More malleable...

More from Global Vision

More from In Vivo